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1. Introduction 
Results from cell transplantation research have received interest and attention both from a 
clinical, a scientific and a public point of view. This chapter discusses new endovascular 
transplantation methods for different cell systems. First different cell based therapies are 
presented, followed by an overview of pathological conditions wherein several cell based 
strategies are implemented. Thereafter the delivery of cells in broad terms, and then 
specifically by endovascular technique compared to surgical technique, is presented. A 
general description of the active process of diapedesis is provided, as it is understood for 
immunological cells, since this is most probably a fundamental process for endovascular 
transplantation of cells as well. 
1.1 Cell based therapies 
Cell based strategies are sought after as a way of repairing or facilitating self renewal in 
pathological organ systems that have little or no intrinsic regenerative capacity. The 
plethora of different diseases in organ systems that might have a regenerative capacity, but 
is limited through physiological processes, is almost boundless (Bajada et al. 2008). Cell 
based therapies have been successfully used in the clinical practice for distinct pathological 
conditions during a relatively long period of modern medicine. One of the broadest success 
stories are the transplantation of cells to patients suffering from hematological diseases 
(Buckner et al. 1974; Thomas et al. 1975; Thomas et al. 1975; Slavin et al. 1998). 
Hematological stem cell transplantation has also been expanded to comprise autologous 
transplantations following chemotherapy of solid tumor forms (Childs et al. 2000). 
Following the isolation of stem cell lines from human blastocysts (Thomson et al. 1998) and 
other adult sources such as the central nervous system (CNS) (Johansson et al. 1999), bone 
marrow (Bruder et al. 1997), multi-lineage mesenchymal (Pittenger et al. 1999), adipose 
tissue (Zuk et al. 2001) among others, new cell based approaches to disease treatment can be 
envisioned. The potential for in vivo expansion of these cells followed by transplantation, re-
implantation and/or tissue engineering becomes possible (Vacanti et al. 1999). These 
findings open up possibilities for strategies aimed at ameliorating disease burden, or in the 
long run, obtaining curative goals through cell therapies in a clinical setting. Proposed 
treatments can broadly be divided into stimulation of an endogenous population or 
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transplantation of cells (Lindvall et al. 2006), be them homologous, from a donor or across 
the xeno-barrier. The wider implications of the prospect of cell based treatments are 
summarized in a review article where the coining of the effort and/or subject of 
Regenerative Medicine is presented (Daar et al. 2007). 
The CNS has attracted attention since the potential of restored function could be very 
valuable for patients. Particularly since pathological conditions in the CNS can be severely 
disabling. Cell based therapies are in clinical trials in e.g. Parkinsons Disease (Freed et al. 
2001; Gordon et al. 2004), ischemic stroke (Kondziolka et al. 2000; Bang et al. 2005) and 
spinal cord lesions (Sykova et al. 2006). Outside the CNS, other clinical trials with cell based 
therapies aimed at e.g. muscle dystrophy (Gussoni et al. 1997; Miller et al. 1997), ischemic 
heart disease (Stamm et al. 2003), graft versus host disease (Le Blanc et al. 2004; Ringden et 
al. 2006) and type I diabetes mellitus (Scharp et al. 1991; Shapiro et al. 2000; Korsgren et al. 
2008) have yielded promising results. So far, many of the cell therapies are still in trials since 
both safety and effects must be thoroughly evaluated. 
In many areas of pre-clinical, and to some extent clinical research, cell based therapies 
deliver positive results. However, as with the definition of stem cells/progenitor cells 
(Potten et al. 1990) the field of cell based therapies are a very heterogeneous one (Bajada et 
al. 2008). One feasible way of applying taxonomy to this field is by discussing different basic 
components in the treated diseases. The first example would be in pathological conditions 
with a definable population of cells being defect. Examples of diseases with certain cell 
types being depleted are Morbus Parkinson - dopamine producing cells, (Lindvall et al.), 
muscle dystrophy -satellite cells of the muscles (Gussoni et al. 1997) and type I diabetes - 
insulin producing cells (White et al. 2001). Such specialized cells might be easier to replace 
than the second general idea of cell transplantation wherein attempts of transplantation is 
aimed at more intricately functioning physiological systems. The complexity increases 
steeply when transplanted cells must differentiate into subpopulations of cell and/or 
interact within networks (e.g. the CNS). An example of that would be the transplantation of 
neural progenitor cells with the aim of full neural integration (Nikolic et al. 2009). A third 
strategy is to exert effects on existing cells/organs through transplantation but without 
functional integration. This strategy might explain some of the results from studies aimed at 
integration of cells, but without engraftment in the target organ, albeit with positive 
functional results observed (Borlongan et al. 2004). One explanation for that phenomenon is 
that in more complex situations, such as following CNS insults, some of the reported 
beneficial effects might be associated with immune modulation or local secretion of growth 
factors, thereby rescuing cells from apoptosis. Examples of immune modulation could be 
Fas-ligand expressing cells (Ghio et al. 1999; Nagata 1999; Lee et al. 2008) whereas secretion 
of growth factors could be exemplified by an over-expression of IGF-1 from transplanted 
mesenchymal cells (Haider et al. 2008). Modulation of the immunological response by cell 
transplantation has also been shown to favorably treat graft versus host reactions in clinical 
practice (Le Blanc et al. 2004; Ringden et al. 2006). The concept of transplantation of cells 
serving as self renewing, local, biologically active, pharmacological factories are attractive 
for many parts of regenerative medicine (Amar et al. 2003). Local, self-sustaining, treatments 
that are only affecting niche parts of organs have many benefits that might include, but are 
not limited to, higher local concentration, less risk of adverse events and customization to 
different pathological conditions. 
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1.2 Delivery of cells 
For cell transplantation, different percutaneous techniques assisted by modern imaging are 
viable through minimal invasive methods (Bale et al. 2007) and most parts and locales of the 
human body can be reached with that approach. On the other hand, for organs with less 
accessible anatomical location, parenchymal access can be associated with significant 
surgical risks (Villiger et al. 2005; Ben-Haim et al. 2009). In situations where engraftment rate 
after intravenous or intra-arterial cell administration is low and when a high anatomical 
specificity is required, such as the scenario when replacing a distinct cell type, direct 
puncture of the parenchyma might be preferable. For CNS applications this can be done 
with stereotactic needle puncture or in a combination with open surgery (Hagell et al. 2002; 
Wennersten et al. 2004). 
Direct parenchymal access can also be achieved by endovascular technique. An example of 
this is a system that adds a possibility to, via large veins, administrate cells to the heart 
parenchyma (Thompson et al. 2003). The design of that system, requiring a large diameter 
catheter and without a closure device for the penetration site makes it usable only in large 
vessels on the venous side, more specifically, in the coronary sinus of the heart (Thompson 
et al. 2003; Siminiak et al. 2005). Other organs that might be difficult to reach, such as the 
CNS and the pancreas, are not reachable by the transvenous technique due to the design of 
that system requiring a large catheter diameter. Furthermore, venous navigation to most 
parts of the CNS and the pancreas, and to certain parts of the heart, is very difficult due to 
the more unpredictable venous anatomy and the venous valves. 
Insulin producing cells are today transplanted by a hybrid method with percutaneous 
access to the portal vein and then intra-luminal cell release in the bloodstream. The concept 
of the intra portal transplantation is considered superior to open surgical techniques, due to 
the un-acceptable risk of adverse events (Kandaswamy et al. 1999; Humar et al. 2000). The 
risk-analysis naturally differs substantially for different surgical procedures and 
transplantations, both with respect to organs and cells. Risks with portal vein 
transplantation include portal vein thrombosis, hemorrhages, and transient increase of 
transaminase values (Shapiro et al. 1995; Ryan et al. 2001). A continuous work of reaching a 
balance between the risk of bleeding after the procedure and portal vein thrombosis is of 
utmost importance for portal vein transplantations and results are improving steadily in 
clinical trials. Further adding to the risk side of the comparison is the need for 
immunosuppressant treatment after transplantation. The potential benefit of the procedure 
must also, as in the case with diabetes and insulin producing cells, be compared to the 
standard treatment of insulin injection and or pumps. Patients eligible  for portal vein 
transplantation of insulin producing cells are thus: patients already subject to 
immunosuppressive therapy due to previous transplantations, patients with unstable 
glycemia, unawareness hypoglycemia, or patients with progressive chronic complications 
despite intensive insulin treatment (Bertuzzi et al. 2006). It has been suggested that it would 
be of great benefit if insulin producing cells could be transplanted directly to the 
parenchyma of the pancreas. Advantages with pancreas as the target locale are e.g. the 
possibility of mimicking the physiological release of insulin and the more hospital micro-
environment for the insulin producing cells; the pancreas has a higher oxygen tension 
compared to the liver (Merani et al. 2008). 
Different strategies of cell based therapies are currently being evaluated in both pre-clinical 
and clinical trials but the cell delivery methods per se have received limited interest. One of 
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the larger obstacles that have been observed, is that the lung acts as a kind of clearance filter 
for the intravenous cell infusion, resulting in pulmonary trapping (Barbash et al. 2003; 
Fischer et al. 2009). An intra-arterial selective approach would possibly result in higher 
transplantation efficiency in certain conditions. The versatility of cell suspensions must not 
be underestimated and limit the way of thinking when considering treatments with cell 
based approaches (Nikolic et al. 2009). The cell suspensions can easily be handled and 
administrated through tubing and catheters, thus providing the possibility to by-pass the 
lung and selectively reach designated target vessels/parenchyma with a first passage effect. 
Those possibilities of cell handling forms the basis for catheter based strategies for cell 
transplantation. 
Endovascular treatments are continuously providing a third option to open surgical or 
percutaneous approaches. From the establishment of the Seldinger technique (Seldinger 
1953) and the first use of digital subtraction angiography (DSA) (Meaney et al. 1980) to the 
modern interventional lab with 3D road maps (Soderman et al. 2005) and CT like capacities 
of the C-arm (Soderman et al. 2008) the path has been long but rapidly progressing. The 
driving force up until today, that has made the leap ward style of improvements possible, is 
both rapid developments in computational power and material sciences. The arteries and 
veins can today be regarded as “internal routes” for navigation, diagnosis and intervention. 
The shift from open surgical options is for example illustrated by the patients that used to 
undergo thoracotomy and that now are being referred for percutaneous coronary 
intervention or the established coiling of intracranial aneurysms instead of open 
neurosurgical operation. 
1.3 Scaling from bench to bedside 
As this chapter hopes to illustrate; the rapid development of endovascular technique has 
implications on cell transplantation methods as well. To illustrate these implications as 
opposed to organ transplantation, one can visualize a liver transplantation. The wound in 
the abdominal wall must at least be big enough for the liver to go into the patient. This 
severely limits the possibility of minimal invasive transplantation of organs. On the other 
hand, the versatility of cell suspensions could make intra-luminal techniques the natural 
way of access. In experimental trials, open surgical options are used in e.g. rodent models 
for transplantation with positive results. This presents a limitation of scalability for 
clinical translation. For instance, when evaluating pre clinical CNS transplantation 
schemes in rodents one or two burr holes are established and cells are transplanted. One 
or two injections in the rat brain covers a relatively large volume but when scaling that to 
the human brain following e.g. a middle cerebral artery ischemic event, a large number of 
percutaneous trajectories would be required to cover a human brain volume 
corresponding to the experimental situation. The migratory capacity for transplanted 
mesenchymal cells after stereo-tactical transplantation has been shown to be around two 
millimeter over 14 days (Chen et al. 2001). Furthermore, the mechanical neuronal injury 
and the risk for intracerebral hemorrhage would increase with each injection trajectory. In 
brain stimulation procedures, the literature is somewhat divergent; the risk for 
hemorrhage could be as high as 5% per injection (Ben-Haim et al. 2009). The easier clinical 
scalability of endovascular access comes in the terms of cells delivered to a larger volume 
of tissue by taking advantage of the already existing vascular system. If an ischemic stroke 
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occurs due to a vessel occlusion at some point, it would be very tempting to 
intraluminally disperse cells from the same point via the vascular system in order to reach 
the affected parenchyma. A normal cell dose for a human adult would probably at least be 
hundredfold higher than in the rodent and needs to spread out over a vastly larger 
volume thus requiring many injection trajectories. The average human brain weight is 
quoted at around 1400 grams as opposed to the adult rat at 2 grams to give some sense to 
the scale proportions. 
Endovascular intervention is not without risks either, exemplified by the risk of adverse 
events reported at 0 to 4.0%, commonly reported at 0.5%, in different cerebral 
interventions (Raymond et al. 1997; Cognard et al. 1998; Ng et al. 2002; Murayama et al. 
2003; Gonzalez et al. 2004; Cronqvist et al. 2005). Added to the risk of the procedure per se 
is the risk of cell transplantations. The risk of intra-arterial transplantation has already 
been documented in humans for up to 24 months without severe complications, albeit in a 
small material (Sykova et al. 2006). Other pre-clinical studies with intra-arterial coronary 
injections performed in healthy dogs revealed micro-infarction of the heart parenchyma 
(Vulliet et al. 2004) whereas that has not been observed in clinical studies (Stamm et al. 
2003). Factors that might be limiting are the size of the cells injected versus the size of the 
capillary system, the proportion of shunts in the microcirculation, the stickyness of the 
cells and the amount of cells administrated. Many of the cells have a much larger 
diameter (10 up to 70 µm) as opposed to the capillaries 5 to 8 µm (Chien et al. 1975). The 
shunting zones in the microcirculation could potentially lead also large cells to the post-
capillary venules where diapedesis usually occurs (Tuma 2008). The main reason for 
leukocyte adhesion/diapedesis through venules is the usually restricted expression of 
adhesion molecules on venular but not arteriolar or capillary endothelium (Tuma 2008). 
In intravital microscopy studies, adipose mesenchymal cells have been shown to act as 
embolic material (Furlani et al. 2009). This risk could be speculated on to be lower than 
the comparable trauma of the surgical methods although a final risk assessment requires a 
randomized clinical trial. 
1.4 Leaving the bloodstream - diapedesis 
One limiting factor to specific intra-arterial and intravenous transplantations is that an intra-
parenchymal approach yields a higher efficacy. It has been shown that when performing 
transplantations to a rodent stroke model and comparing intravenous, intra-ventricular and 
intra-striatal injections, the highest efficacy in sheer number of cells were obtained with the 
intra-striatal route (Jin et al. 2005). Further limiting the selective intra-luminal approach is 
the speculation that some cell systems, such as insulin producing cells, appear incapable of 
leaving the bloodstream (Hirshberg et al. 2002). 
In all implementations aimed at intra-luminal administration (intra-luminal encompassing 
both intravenous and selective intra-arterial administration) the ability of the cells to leave 
the bloodstream, or perform diapedesis (Fulton et al. 1957) is fundamental. The diapedesis 
function has previously been studied predominantly in immunological cells (Fulton 1957), it 
is in fact the active process whereby cells leave the bloodstream. The diapedesis of 
immunologically active cells has been thoroughly studied since the discovery of the 
significant multistep, ordered, cross-talk procedure of leukocyte-endothelial cell interaction 
both in vitro and in vivo (Butcher 1991; Springer 1994). 
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The barricades limiting the cells from haphazardly leaving the bloodstream are many. All 
blood vessels contain an endothelium and several organized barriers. In the CNS for 
instance, tight junctions are located between endothelial cells, predominantly to permit the 
conservation of the water fraction of the blood stream. The liquid pressure gradient 
composed of the blood pressure can be broken down to one force directed with the axis of 
the laminar flow of blood and one force aimed perpendicular to the flow on to the wall 
(Glagov et al. 1992; Fay 1994), thereby providing an evolutionary rationale for sealing the 
blood stream tightly. Situated underneath the endothelial cells and forming their structural 
base is the basal layer; a specific protein structure composed of extra cellular matrix (ECM) 
proteins abundant with expression of elastin, laminin and collagen type I, III and IV (Mayne 
1986). Collagen and elastin are the major structural components of blood vessels of all sizes 
throughout the mammalian body. The cross-banded fibrils in the tunica media and tunica 
adventitia, formed by type I and type III collagen, provide the tensile strength and comprise 
probably 80 to 90% of the total collagen present. The other major structural protein 
component in elastic arteries is elastin; the protein that provides the elastic component of the 
blood vessels (Mayne 1986). Around most capillaries, pericytes are situated which further 
seal the blood stream. The pericytes are less abundant in the post capillary venules where 
most of the diapedesis occurs. As a general note, the post capillary venules are the most 
“leaky” part of the vascular tree. It should be noted that blood vessels are not merely the 
plumbing in the mammal body, they are in all respects a vividly living part of the organism, 
reorganized as a response to stress and demand (Gibbons et al. 1994) and among other 
things have a self-generating electro potential towards the bloodstream that is important for 
the clotting cascade (Danon et al. 1976). 
As previously mentioned, in a diverging literature, it has been speculated that some cells 
totally lack the function of exiting the blood stream, thereby limiting intra-luminal based 
techniques. Even though insulin producing cells appears incapable of leaving the 
bloodstream, they are still transplanted through the portal vein (Hirshberg et al. 2002). The 
mechanism of action is believed to be microembolization of the cells to the liver parenchyma 
in the low pressure system that the portal vein constitutes (Lehmann et al. 2007). It has been 
speculated that arterial blood from the hepatic artery pushes back into the portal vein 
during the mixing of the two flows which would stop the cells and create advantageous 
conditions for engraftment. The cells found functioning in the livers of transplanted patients 
are, however, situated as plaques in the hepatic artery tree thus adding yet another hurdle 
to the understanding of portal vein transplantation. The hypothesis is that the cells cannot 
perform diapedesis but are instead primarily forming a mural thrombus after, with low 
probability, being displaced against the blood flow into the arterial tree and then 
encapsulated by endothelial cells. The plaque formation can thereby provide capillary 
ingrowth, an absolute requirement for endocrine function (Korsgren et al. 2008). Such a 
hypothesis would also shed further light on the low efficacy of portal transplantations 
methods. Nevertheless, the portal vein approach to transplantation is today the golden 
standard since the existing open surgical options of total pancreatic transplantation carries a 
mortality risk of 10% during the first year of follow-up (Kandaswamy et al. 1999; Humar et 
al. 2000). 
The process of diapedesis is basically divided into tethering, rolling and stopping of 
leukocytes prior to diapedesis into inflamed tissue. It is thought of as a multistep procedure 
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involving complex crosstalk between cells in the bloodstream and the endothelial cells. 
On the endothelial side intra-cellular adhesion molecule -1 (ICAM-1) (Dustin et al. 1986; 
Rothlein et al. 1986), vascular cell adhesion molecule -1 (VCAM-1) (Elices et al. 1990; 
Pulido et al. 1991) and junctional adhesion molecule –A (JAM-A) have all been implicated 
to play crucial roles. Interestingly, all of these receptors are part of the Ig-super family. 
Leukocytes capacity for homing and diapedesis is pivotal for the development of the 
inflammatory response to injury and starts as a tightly controlled up-regulation of 
endothelial E- and P-selectins that stimulate the leukocytes (Vestweber et al. 1999). These 
leukocytes then respond by activation of G protein-coupled receptors that increase the 
affinity for endothelial VCAM-1 and ICAM-1 (Muller 2003). Interaction with VCAM-1 is 
maintained through the heterodimer CD29 and CD49d forming the cell surface antigen 
Very Late Antigen – 4 (VLA-4) (Elices et al. 1990) and the CD11aCD18 heterodimer 
interacting with ICAM-1 (Meerschaert et al. 1995). VCAM-1 and ICAM-1 have previously 
been shown to be up-regulated on the endothelium as a response to inflammation (Dustin 
et al. 1986; Pulido et al. 1991). This interaction starts the diapedesis itself wherein the 
leukocytes “crawl” through, either a para-cellular or a trans-cellular pathway interacting 
with both PECAM-1 and/or CD99 or members of the JAM family of proteins (Petri et al. 
2006). Thus significant crosstalk is needed to initiate and execute the active process of 
diapedesis. 
VCAM-1 is also implicated both as a model of treatment for immunological modulation of 
the inflammatory responses following CNS insults and as surface antigen for cell 
treatment of CNS insults. In one study, fluorescence activated cell sorting (FACS) was 
performed for the expression of CD49d and identifying it as one of the important factors 
for directing diapedesis (Guzman et al. 2008). This finding has received a lot of interest 
from different fields, among other it has been shown that VCAM-1 expression has a 
critical role in transplantation of cells in dystrophic muscle (Gavina et al. 2006). Another 
utilization of VCAM-1 is the selective blocking by the monoclonal antibody drug 
Natalizumab used in multiple sclerosis, thereby inhibiting diapedesis for 
immunologically active cells (Stuve et al. 2008). VCAM-1 blockade has also been tested for 
neuroprotective effects following ischemic events in pre-clinical trials with disappointing 
results (Justicia et al. 2006). 
2. Results and discussion with emphasis on the central nervous system 
In this chapter three different types of endovascular methods of cell transplantation are 
discussed. The first two are the selective intra-arterial  and the intravenous methods, these 
are compared for efficacy. The third method is the trans-vessel wall technique by using the 
Extroducer; an endovascular catheter system developed within our group for penetrating 
the vessel wall from the inside to out, thereby creating a working channel to extravascular 
tissue. 
For certain cell types, the selective intra-arterial method is superior to the intravenous one 
after TBI in the rat. This was measured by the level of engraftment of hMSC at one and five 
days following TBI, without thrombo-embolic complications (Lundberg et al. 2009). 
Selective intra-arterial transplantation method for rNPC after TBI in the rat is also superior 
compared to intravenous method. We were, however, not able to engraft hNPC, ceteris 
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paribus, thus indicating that diapedesis and engraftment is an active process and that 
different cell systems have different capabilities to engraft following intraluminal delivery 
(Lundberg et al. 2011). We show, by indirect methods, that CD29CD49dVCAM-1 
interactions might be one of the factors with impact on engraftment in an intra-luminal 
transplantation setting (Lundberg et al. 2011). Further, we show that it is possible to perform 
minimally invasive parenchymal injections by trans-vessel wall technique by the 
development of the Extroducer (Lundberg et al. 2010). The Extroducer have no adverse long 
term effects on the blood vessels up to 3 months following interventions (Lundberg et al. 
2011) and it is feasible to use the system as a novel approach for transplantation of e.g. 
insulin producing cells to the CNS, to the pancreas or other cell types to organs that are 
difficult or risky to reach by traditional methods. The trans-vessel wall technique thereby 
adds a new possibility when transplanting cell populations without the necessary properties 
for performing diapedesis. The establishment of a working channel to the extravascular 
tissue, by endovascular method, also opens up several other possible applications, such as 
different methods for sampling. 
2.1 Selective intra-arterial method versus intravenous method 
We established a model for selective intra-arterial transplantation (Lundberg et al. 2009) that 
we applied to a model of TBI in the rat (Feeney et al. 1981). We compared the selective intra-
arterial method to intra-venous methods for different cell systems in the same TBI setting. 
Several different variables were tested such as cell concentration, days post injury for 
transplantation, time for infusion, level of immunosuppressant drugs etc. The majority of 
transplantation experiments were not successful from the start and many different variables 
were tested before robust engraftments could be reached. Too few cells had a dire impact on 
the success of transplantation; 200.000 (unpublished results) and 500.000 hMSCs did only 
result in very low engraftment. The failure of low cell numbers can obviously be interpreted 
as an indication that the efficacy of the intra arterial method in this setting is quite low 
although it is still superior to intravenous alternatives. 
Results of engraftment levels were obtained through IHC methods by counting engrafted 
cells in sectioned brains (Fig 1). We found that engraftment levels of rNPCs were more than 
five-fold higher than in the control group (p=0.034) and hMSC were more than fifteen-fold 
higher than the in control group in absolute values (p=0.007), with a large spread within the 
intra-arterial groups (Fig 2). Few studies compare selective intra-arterial and intravenous 
methods but recent clinical data suggest an advantage for the selective intra-arterial route 
(Sykova et al. 2006). A known problem with all intravenous methods is the fact that the lung 
acts as a kind of clearance filter during the first passage (Barbash et al. 2003; Fischer et al. 
2009). Following intravenous cell infusion, the blood transports the cells after venous 
passage to the right ventricle and then through the lung where up to 80% of cells are 
trapped during the first passage (Fischer et al. 2009). Thus as low as 20% of the cells 
transplanted might be ejected for the first total body distribution through the aorta. Of all 
the blood leaving the left ventricle of the heart, only somewhere between 1.8 to 8.5 percent 
of the blood actually reaches the brain of the rat (Pannier et al. 1973) leaving only 0.01 to 1.7 
percent of the initially transplanted cells to reach the brain in the first passage. All cells not 
distributed to the brain are then again re-transported for another passage through the lung, 
acting as a filter. This phenomenon has been studied e.g. by PET for mesenchymal stem cells   
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Fig. 1. Representation of intra-arterial transplantation in the TBI model 
In the background is a reconstructed image showing a coronal section of the rat brain 2.5 
mm posterior to bregma stained with GFAP (red) and NeuN (Brown) five days after 
traumatic brain injury. In blow-up a. a low magnification single staining with HuN (human 
nuclear antigen, MAB 1281) without any counterstaining, along the peri-lesional zone is 
shown. Brown dots represent HuN positive, transplanted cells (arrow indicates an example 
of a positive cell). In blow-up b. the black area represents the contusion zone and the grey 
areas represent primary localization of engrafted mesenchymal stem cells. In blow-up c. a 
magnification of the injury area itself is presented. 
(Ma et al. 2005). This situation can readily be changed by placing a micro-catheter in the 
arteries supplying the organ of interest. An interesting finding in the present study is that 
our hMSCs predominantly were found in the spleen with few transplanted cells in the lung 
at 24 hours post injection, a bio-distribution phenomenon, from the lung to the spleen, 
previously described in rat following intravenous hMSC transplantation (Detante et al. 
2009). To increase the understanding of the role of cell line properties for engraftment, we 
conducted a study with transplantation of different cell lines through either intra-arterial or 
intravenous routes. This analysis showed that there were dramatic differences between the 
different cell lines; hNPCs did not engraft at all after intra-luminal delivery whereas there 
was a significant difference between the hMSCs and the rNPCs using the same 
transplantation method. Noteworthy is the large variability in the engraftment levels of the 
latter two cell lines. One important factor that might contribute to this is that neither hMSC 
nor rNPCs are defined homologous cell lines, succinctly there can be important variations 
within the cell systems transplanted. The remarkable finding that no engraftment was 
obtained following hNPC transplantations is even more noteworthy since the hNPCs have 
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previously been robustly transplanted by open surgical technique (Wennersten et al. 2004; 
Akesson et al. 2007). 
 
 
Fig. 2. Graph illustrating engraftment levels 
Engrafted cells were counted per section and is reported with median (marker), quartiles 
(box) and max – min (whiskers). In A a significant difference between engraftment levels 
per section following selective intra-arterial and intravenous transplantation in the 
ipsilateral hemisphere of the rNPC group. In B a significant difference between engraftment 
levels per section following selective intra-arterial and intravenous transplantation in the 
ipsilateral hemisphere of the hMSC group and finally in C a panel of all engraftment levels 
per section in the ipsilateral hemispheres of all groups. * marks p < 0.05 
2.2 Gene expression profiling of cell systems 
After discovering that there were differences in engraftment capability between the different 
cell lines, the opportunity to investigate the bio-molecular basis of said differences presented 
itself. We started with characterizing and confirming earlier results (Clausen et al. 2007) that 
our TBI model leads to up-regulation of VCAM-1 expression in the endothelium. That result 
may suggest that the injured CNS parenchyma could provide cues for diapedesis and 
migration of engrafted cells in similar ways as immunological cells respond to inflammatory 
cues (Butcher 1991; Springer 1994). As a screening method, we started by performing 
microarray on the human cells. rNPCs were not included in the microarray analysis due to 
problems with cross-species comparisons in the microarray chips used. hMSCs showed a 
broad expression of integrins, commonly expressed by immune  cells, that are important for 
diapedesis through the vessel endothelium and subsequent migration into the parenchyma. 
Specifically, analysis of the heterodimers forming receptors for ICAM-1 and VCAM-1 were 
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analyzed, based on previous work indicating CD49d expression as important for successful 
intra-vasal transplantations (Guzman et al. 2008). Thus, probably the most interesting 
finding was the CD49d signal of 68 in hMSC as opposed to 0.4 in hNPC (p=0.0047). This was 
then confirmed with RT-qPCR data from all cell lines with average CD49d mRNA levels 
that were highest in the hMSC (0.98) followed by the rNPC (0.0057) and finally a dwindling 
finding in hNPC (0.0012). CD29 and CD49d forms a heterodimer named very late antigen -4 
(VLA-4) which was expressed in falling order in hMSC, rNPC and hNPC (Fig 3). The 
difference in mRNA levels between rNPC and hNPC is not large but might reflect larger 
differences in protein translation. Further studies at the protein and functional level are 
required to elucidate the importance of CD49d for diapedesis of these cell systems. CD11a 
mRNA was detected in hNPC (0.0029) albeit with low CD18 mRNA (0.00025), suggesting 
that CD11a-CD18-ICAM-1 interaction may be dispensable for engraftment. In contrast, 
hMSC displayed high CD18 mRNA levels (0.43) but no detectable CD11a expression, 
suggesting neglectable ICAM-1 dependent engraftment in the hMSCs. 
 
 
Fig. 3. RT-qPCR results from Cell systems 
Bars represent relative levels of integrin CD49d, CD29, CD11a and CD18 mRNA expression 
in rNPC, hNPC and hMSC compared to respective endogenous TBP mRNA levels. Error 
bars represent the distribution between the biological replicates. 
Finally, both our own findings regarding hNPCs and other previously known cells 
incapable of diapedesis, such as insulin producing cells (Hirshberg et al. 2002), shows the 
apparent need for surgical techniques. In some organs that are hard to reach and/or when 
surgical technique comes with a high risk of adverse events for the patients, the need for an 
alternative strategy becomes apparent. Thus, we also initiated the development of the trans-
vessel wall approach. 
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2.3 Trans-vessel wall transplantation 
An endovascularly based system that could penetrate the vessel wall would, in instances 
where the target parenchyma is either hard to reach or carries a significant surgical risk, be a 
method with both the merits of accurate placement and reduction of patient risk. Further, it 
would solve the problem for certain cells to leave the bloodstream. A proposed solution to 
this problem is a endovascular catheter system that we have named the Extroducer 
(Lundberg et al. 2010). 
2.3.1 Extroducer in vivo testing - small animals 
After extensive computer simulations and ex vivo testing, in vivo short term testing were 
performed in rat by creating arterial access from the medial tail artery and performing the 
Extroducer trans-vessel wall technique passage in either the subclavian or carotid artery. 
Two different stages of the procedure was tested; first the trans-vessel wall technique 
passage per se with surgical microscope monitoring of hemorrhage or other adverse events, 
and thereafter the deployment of the distal penetrating tip through the vascular wall and 
retracting the proximal part of the system. No cases of intra-operative hemorrhage or intra-
luminal thrombosis occurred. Thus, the vascular penetration procedure was uneventful and 
the vessel wall completely sealed around the Extroducer, thereby preventing leakage of 
blood. 
The second group with deposited Extroducer tips also showed absolute hemostasis during 
the primary intervention. Fourteen days post intervention, this group showed no signs of 
pain or discomfort. No signs of dissection of the vessels or impairment of blood-flow distal 
to intervention sites were observed and macroscopical analysis of the organ supplied by the 
vessel, showed no infarcts. 
With computer-based flow simulations, we found that there should be no blood-flow 
through the detached Extroducer interior lumen at physiological blood pressure. This was 
also tested in vivo by cannulating the deployed distal tip of the prototypes with a nitinol 
mandrel. This was done to reassure that even when removing possible clotting inside the 
prototype, it still prevented bleeding from inside the vessel to the extravascular space. 
Furthermore, no signs of delayed hemorrhage were detected. 
2.3.2 Extroducer in vivo testing - large animals 
After successful trials in small animals, the Extroducer system was tested in large animals. 
An adaptation towards clinical use was that these prototypes were manufactured from a 
longer nitinol tube, 1700 mm vis-à-vis 300 mm that was used in the rat. We evaluated the 
prototypes in the rabbit together with standard clinical catheters and angiographical 
equipment. 
The Extroducer prototypes within the microcatheters were visible at high magnification 
fluoroscopy and thereby maneuvered into the subclavian artery (SCA) (Fig 4). The rabbit 
SCA was chosen since it is close to the intended target vessel size of 0.5 to 3 millimeters, the 
SCA is fairly easy to access in order to perform simultaneous open surgical monitoring and 
it had been used in the rat. A slight amount of pressure was required on the protecting 
plastic catheter to advance the system through the microcatheter to the desired vessel wall, 
thereafter the Extroducer was gently advanced out through the vessel wall to the extra-
vascular space. Hemorrhages were neither observed by simultaneous direct observation 
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through a surgical microscope, nor by high resolution angiographical series (DSA), during 
and after the intervention (Fig 4). Further, no thromboembolic complications or vascular 
dissections were observed using high resolution DSA. No navigational problems were 
encountered with respect to Extroducer prototype integration with clinical catheters. 
 
 
Fig. 4. Trans-vessel wall interventions 
For full control over the procedure in the large animal trials, both a surgical microscope and 
high resolution angiographical series was used. In a. digital subtraction angiogram showing 
a detached Extroducer tip without hemorrhage, dissection or thromboembolic 
complications. In b. photograph showing the microsurgical view of the detached Extroducer 
tip. In c. x-ray image showing the detached Extroducer tip with guide catheter. In d. 
photograph from post-operative dissection showing the detached Extroducer tip with 
methylene blue injected in the surrounding tissue. In e. digital subtraction angiogram 
showing an extra vascular injection of 25 µl contrast agent through the Extroducer system. 
Finally, electrolysis detachment of the distal Extroducer distal tip was tested in rabbit. We 
chose electrolysis since it was the easiest way of performing detachment in our hands. Our 
design was  based on the work of the first detachable coils (Guglielmi et al. 1991). An 
important difference compared to the detachment zone in coils was, however, that we 
needed a hollow detachment zone which required additional development. After navigation 
to the designated intervention site and after methylene blue or contrast agent had been 
deposited in the extravascular space, a tension of 8V was applied and the distal tip was then 
detached after, on average, five minutes (range three to nine minutes). This was also un-
eventful without observation of hemorrhage from around the body of the distal tip or 
through the inner lumen. The procedure was successfully performed both with 
simultaneous microscopical monitoring via surgical access, and with 
fluoroscopical/angiographical guidance solely. In a previous work describing a method for 
penetrating large veins (Thompson et al. 2003), that system design required a much larger 
catheter and also lacked a method for sealing the vessel wall, thus making penetration 
through the arteries impossible. This severely limits the use of that system to their testing 
www.intechopen.com
 
New Advances in Stem Cell Transplantation 172 
vessel, i.e. the sinus coronarius of the heart, whereas the Extroducer is applicable in both 
arteries and veins of any sizes down to approximately 0.5 mm in diameter. Another system, 
in which vessel perforations are performed, is the trans-jugular intrahepatic portacaval stent 
shunt (TIPS) technique (Richter et al. 1990). That system also does not have the requirement 
of sealing the vessel wall when finishing the procedure, since a patent blood flow through 
the stent is the preferred result. On the contrary, thrombosis of the stent might be 
considered the main problem (Merli et al. 1998) which requires rigorous follow-up. 
Thus, the Extroducer system is unique in the ways that it permits safe exit of both arteries 
and veins and that it is usable in vessels with large dimensions as well as in the 
microvasculature with inner lumen diameters down to approximately 0.5 mm. 
2.2.3 Extroducer testing with long time follow up 
In a long term follow up, the end points five days, one month and three months after the 
deployment of the device was selected. No stenosis or late hemorrhagic complications were 
noted in any animals. No alterations in behavior or other measures of discomfort were 
noted either (Lundberg et al. 2011). 
The distribution of followed up animals were as follows; two at the five days end point , five 
at the 30 days end point and six at the 80 days end point with histological analysis of one 
resulting in a total number of 19 detached Extroducer tips. 
In the follow up DSA we also found that four of 19 (21 %) of the detached tips were no 
longer placed through the vessel wall but had instead been “pushed” or “migrated” through 
the endothelium to the extravascular space immediately adjacent to the penetration site. No 
vascular stenosis or other adverse reactions were observed around those tips. Also for the 
rest of the tips, that were located through the vessel wall, no adverse reactions were 
detected. An important endpoint was biocompatibility of the detached tips. The nitinol alloy 
used was selected for its many advantageous properties. Nitinol is a nickel/titanium alloy 
with both memory and super elastic properties (Adler et al. 1990). These special properties 
are the foundation for the use of nitinol in stent fabrication in clinical practice. Thus, the 
excellent biocompatibility of nitinol (Castleman et al. 1976) has been extensively studied, 
especially with respect to vessel wall interactions in the use of stents (Stoeckel et al. 2004). 
However, the compatibility of nitinol when placed through arterial walls has, to our 
knowledge, not been studied. The parylene, used as coating in our device, is also FDA 
approved and CE marked when used in pacemaker electrodes. To evaluate interaction 
between the deposited tips and the endothelium, we performed histological analysis with 
the prototypes in situ by a specialized grind-cutting technique and then consulted an 
external, independent, evaluator with expertise in the field of titanium implants. This 
evaluation showed full biocompatibility with a very small fibrotic capsule (< 1 µm) formed 
around the detached distal tips (fig 5). No ongoing inflammation was observable around 
any of the distal tips. Around one (of the total number 14 left in place) of the day five animal 
implants, three macrophages were indentified in the area of the detached distal tip. Apart 
from those three macrophages, no other signs of inflammation were observed. The 
endothelia showed no signs of alterations adjacent to the deposited tips. 
In conclusion, the biocompatibility of the distal tips was comparable to titanium implants. 
The interactions of nitinol with the interior of the vascular wall and the extra vascular space 
has not been as extensively studied since stents most often are positioned inside the vascular 
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lumen with direct contact only with the bloodstream and the endothelium. Therefore, the 
present histological analysis in this new application and new position of nitinol, adds 
important knowledge about biocompatibility for possible future applications. 
 
 
Fig. 5. Long term follow-up of the trans-vessel wall intervention 
In a. the initial follow up angiogram directly following detachment in the Superior 
Mesenteric Artery (SMA) is shown with a square marking the blow-up in b. Arrows indicate 
the detached distal tip. In c. an SMA angiogram, performed 80 days after the intervention in 
the same animal, is shown with a square indicating the blow-up in d. Arrows indicate the 
detached distal tip. In e. a microphotograph of a histological van Geeson and toulene blue 
staining prepared by grind-cutting with the detached tip in situ, is shown. Scale bar = 100 
µm. The blow-up in f shows the parylene coating surrounding the detached tip which is 
marked by an arrow. Note that no fibrous response or inflammation is observable. Scale bar 
= 4 µm. 
The prototypes excluded due to failed detachment were analyzed by sweep electron 
microscopy (SEM), since monitoring of electric current gave limited prognostic information 
about the failure to detach. We found that, in failed detachments, large amounts of chloride 
were observed by surface spectroscopy (6-10 wt %) indicating titanium chloride ion 
formations in a passive layer, thus providing current transmission without electrolysis. 
Titanium chloride molecules can provide a surface area that lets electron pass through but 
without formation of soluble titanium or nickel ions. This problem is probably due to the 
simple technique used for creating the insulation defect in our hands. However, numerous 
available solutions for detachment are available on the market that can easily be integrated 
with the trans-vessel wall technique in an industrialized manufacturing process. 
3. General discussion 
The rationale for our previous studies within the field of endovascular cell transplantation is 
the path to translating cell based regenerative medicine to patients. In a translational 
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perspective the actual route of transplantation will be important. For operative techniques 
there is a problem with scalability and for intravenous techniques there is a problem with 
efficacy. We show that by selective intra-arterial methods it is possible to increase the level 
of cerebral engraftment with certain cell types with six to fifteen fold yields. Further, not all 
cells are optimal for intra-luminal transplantation. It is, for example, known that insulin 
producing cells lack the capability to perform diapedesis (Hirshberg et al. 2002) and we 
show that hNPC, a cell system previously transplanted by open surgical means (Wennersten 
et al. 2004) also lacks the capability to perform diapedesis. For these cell systems, and other 
applications, we have developed the Extroducer as a tool to establish a direct, minimal 
invasive working channel with parenchymal access in organs that are difficult or risky to 
reach with traditional techniques. 
The first passage of cells delivered through selective intra-arterial approaches, compared to 
systemic intravenous delivery, results in a higher local concentration, shorter blood stream 
exposure and less mechanical stress factors before cells reach the target site. These factors 
could be of importance for successful engraftment. Supporting that hypothesis are the 
present results showing significantly higher total cerebral uptake of cells after intra-arterial 
compared to intra-venous administration. The next supporting fact is the higher uptake of 
cells in the ipsilateral hemisphere after intra-arterial administration and by the absence of 
difference between the hemispheres after intravenous transplantation. Future studies are 
needed for elucidating molecules responsible for diapedesis, e.g by direct methods such as 
knock-ins, of for example CD49d, in non-functioning cell systems and knock down or 
blocking in other cell systems. 
The absence of adverse effects in transplanted animals suggests that in the short term, the 
selective intra-arterial transplantation method is safe for delivering even high concentrations 
of cells. It has been reported ischemic events following intra-arterial approaches to the heart 
in dogs (Vulliet et al. 2004) thus indicating the need for thorough studies prior to translation 
into clinical practice. However, in clinical studies on intracoronary infusions (Stamm et al. 
2003) and in spinal cord artery infusions (Sykova et al. 2006) no embolic events have been 
recorded. Connected to the need for safety studies, it could be argued that the higher 
engraftment rates in our intra-arterial groups would be a consequence of microembolization 
of cells. In that scenario we would, however, have detected ischemic histological changes 
and localization of the transplanted cells within arterioles and capillaries, which we did not. 
For all intra-luminal approaches, this thesis shows that a thorough investigation must be 
performed to clarify if the cells actually can perform diapedesis prior to choosing 
transplantation strategy. hNPCs has previously been shown to have an impact on 
neurological outcome when transplanted with open surgical techniques, but in their present 
form they seem unsuitable for intra-luminal transplantation. Therefore, based on the 
findings in this thesis, considerations should be made that CD29CD49dVCAM-1 interaction 
is one of the best studied crosstalk mechanisms on how immunological cells leave the 
bloodstream to perform homing to disease ridden tissue where inflammation occurs (Elices 
et al. 1990). This line of reasoning is supported by other studies implicating VCAM-1 
interaction in both ischemic stroke and muscle dystrophy pre-clinical studies (Gavina et al. 
2006; Guzman et al. 2008). An interesting comparison can be made regarding diapedesis in 
cell systems aimed for transplantation compared to immunological cells. In such an exercise 
it could be considered blatantly ignorant to immediately dismiss the fylogenetically 
conserved mechanism of the immunological system and suggest a hitherto unknown 
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method of diapedesis for these cells. Applying Occam’s razor to the hypothesis of 
diapedesis for cell transplantation, two conclusions can potentially be made; i) the process of 
diapedesis is most probably an active process for cell systems transplanted, since there are 
no known inactive ways of diapedesis and ii) the most likely system for diapedesis crosstalk 
should be found within the same systems that are used by the immunological system, 
meaning that proteins are highly likely to come from the Ig-super family such as VCAM-1. 
The other, more complex, explanation would be that a hitherto unknown system for 
diapedesis exists. That it also unlikely since mutations in such a system would lead to 
genetical diseases that should be known, but without reasonable explanations. A research 
program dedicated on endovascular transplantation of different cell systems in different 
diseases should include a variety of diseases and cell systems to increase the understanding 
of both cell-endothelium interactions and the effects on target niches. 
When designing both pre-clinical and clinical cell transplantation studies, consideration 
should be taken to how the cells are hypothesized to reach their designated targets. The first 
option might be open surgical techniques for small niche locations in a target parenchyma. 
Downsides to open surgical/percutaneous techniques are e.g. impracticalities of accruing 
the desired extent of target tissue volume, especially if the volume is relatively large, such as 
following a major CNS insult. Further, the patient risk for adverse events might be 
unacceptable in relation to a potential benefit, in particular for “difficult to reach” organs 
such as the CNS, the pancreas and/or the heart. If the disadvantages of open 
surgical/percutaneous techniques are unacceptable, intra-luminal options could be 
explored. For intra-luminal approaches, the concept of how transplanted cells are presumed 
to leave the blood stream becomes an issue with several potential solutions. For a cell 
system without the necessary features for diapedesis, one could use knock-in methods to 
provide the necessary adhesion molecule set up, otherwise intra-parenchymal injections 
must be considered. For knock-in methods, an intra-arterial approach would probably still 
have benefits in efficacy over intravenous methods through the first passage effect and by 
avoiding pulmonary trapping. As previously discussed, an interesting purely academical 
calculation when performing intravenous cell transplantations could result in such a low 
cell dose to the brain as 0.01 to 1.7% after intravenous injection, assuming that 80% of cells 
are trapped in the first passage through the lung (Barbash et al. 2003; Fischer et al. 2009). 
This can readily be changed by placing a micro-catheter in vessels supplying the target 
parenchyma with blood thereby providing a chance for all cells to perfuse the target 
parenchyma. 
For more discrete functioning cells, an intra-parenchymal injection might be even more 
attractive for reasons such as shielding the cells from the exposure to the bloodstream and 
accurate anatomical placement. In difficult to reach organs, minimally invasive direct 
parenchymal transplantation could be performed by the trans-vessel wall technique 
described within this thesis. That technique might, however, not be suitable for treating a 
large ischemic lesion in humans. On the contrary, in discrete lesions where only a niche cell 
needs to be replaced, such as in type I diabetes, where the cells do not possess properties for 
diapedesis, the Extroducer could potentially really show its worth. The next natural step is 
transplantation of insulin producing cells to swine before planning for clinical trials.  
The Extroducer is not limited to cell transplantation. Its main design is to provide a working 
channel by endovascular technique to the parenchyma in various, otherwise, inaccessible 
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organs. Through that working channel, other procedures such as local chemotherapy-, 
irradiation-, growth factor administration, tissue sampling, electrophysiological diagnostics 
and thermo-therapy becomes possible. Further, combined with optical spectroscopic 
analysis, it might even be possible to perform infra-light histological analysis of tissue via 
the Extroducer. 
3.1 Conclusions and future research 
We have discussed the rationale for using endovascular methods for cell transplantation 
and described findings from our group and other groups, showing that selective intra-
arterial administration is a safe way, with a short follow up time, to increase engraftment 
levels compared to intravenous delivery. However, not all cell systems are optimal for intra-
luminal transplantation. These factors might be dependent on integrin expression and 
endothelium interactions. For cells that lack the capacity to perform diapedesis, and 
especially for more specific niche cell systems in organ systems that are difficult to reach, we 
have also developed a system for trans-vessel wall parenchymal access. The Extroducer 
system has been evaluated both for long term effects and feasibility for pancreas access. 
Ergo, endovascular intervention should provide a number of methods for efficient and safe 
cell transplantation in current and future clinical practice. The transplantation method must 
be decided on a disease to disease, cell to cell and patient to patient manner. Future research 
should investigate the possibilities of providing cells meant for intravasal transplantation 
with the necessary properties for performing diapedesis. 
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